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Synopsis for thesis entitled, “Evaluation of 
early pathogenic mechanisms of synaptic 
dysfunction in Alzheimer’s disease”: 
Alzheimer’s disease is a debilitating, progressive 
neurodegenerative disorder in the elderly, characterized by 
severe loss of memory and higher cognitive functions. In the 
hundred years since its discovery, Alzheimer’s disease (AD) has 
traversed from the status of a ‘rare neurological oddity’ to one 
of the greatest challenges faced by healthcare and medicine in 
this millennium. A reported 44 million people currently suffer 
from AD but only 1 in 4 people have been diagnosed. Although AD 
has been an area of intense research for almost 50 years now, 
most studies have focused on the end stage disease. Years of 
study on the pathological cause underlying AD, have conclusively 
shown that the accumulation of the sticky peptide, Aβ, is one of 
the major triggers of AD pathogenesis. However, after the 
initial Aβ trigger, multiple processes contribute to disease 
progression, so that by the time a patient is diagnosed on the 
basis of overt behavioral phenotypes, it is difficult to 
understand and differentiate between the causative mechanisms 
and the consequential effects of the disease. It is, perhaps, 
because of this, that we are still struggling to find therapies 
for AD which will stop or at the very least slow the course of 
the disease. In the 2015 report on AD, issued by the Alzheimer’s 
association, much emphasis has been placed on the early 
diagnosis of AD and the revision of the diagnostic criteria for 
AD. According to the new guidelines proposed in 2011, AD has 
been divided into three stages where the first stage occurs 
before the appearance of overt behavioral symptoms such as 
memory loss, whereas by the 1984 guidelines, cognitive 
disabilities must have already occurred for diagnoses of AD. 
This proposed preclinical stage of AD has been defined, 
reflecting the current belief that AD pathogenesis begins almost 
20 years before the occurrence of behavioral dysfunction. 
However, no diagnostic criteria are currently available to 
establish this stage. Hence, there is a need to understand the 
early pathogenic mechanisms of AD, which will yield early 
therapeutic targets as well as early diagnostic markers of AD. 
One of the earliest documented events in AD pathogenesis is 
synaptic dysfunction, which is later manifested as loss of 
dendritic spines. Deficits in long term potentiation (LTP) has 
been demonstrated in Aβ exposed hippocampal slices as well as in 
mouse models of AD, much before the appearance of pathological 
hallmarks such as plaques and tangles as well as overt 
behavioral phenotypes. While these and other studies indicate 
clearly that elevated levels of soluble Aβ peptide leads to 
impairment of synaptic function, the underlying molecular 
mechanisms are yet to be elucidated. One of the purported 
mediators of Aβ induced dysfunction is oxidative stress. The Aβ 
peptide, especially the Aβ42, is a self aggregating peptide with 
a propensity to form peptidyl radicals. Interaction of the 
peptidyl radicals with biomolecules leads to the generation of 
more free radical species via cascading chain reactions. 
Additionally, Aβ peptide has also been demonstrated to have 
synaptotoxic effects via its effect on NMDA receptors and 
calcium influx leading to deregulated reactive oxygen species 
(ROS) production as well as excitotoxicity. 
Hence, with a view to understanding Aβ mediated early synaptic 
dysfunction in AD, we studied early signaling changes in the 
synaptosomes derived from the cortex of APP/PS1 mice model of AD 
at various ages. The APP/PS1 model contains a mouse/human 
chimeric APP gene bearing the KM670/671NL Swedish mutation and 
the human PS1 gene with an exon 9 deletion. These mice exhibit 
behavioral deficits from 7 months of age while plaque deposition 
and gliosis become apparent by 9 months of age. We chose to 
study both pre-symptomatic ages (1 and 3 months old) as well as 
post symptomatic (9 months old) mice. Post nuclear supernatant 
(PNS) as well as synaptosomes were isolated from the cortex of 
APP/PS1 and age matched control mice. We assayed the levels of 
reactive oxygen species (ROS) in the PNS and the synaptosomes of 
post symptomatic 9 months old APP/PS1 mice and age matched 
controls. In contrast to reports of enhanced oxidative stress 
markers in the brains of AD patients, we did not find any 
increase in the levels of ROS in the PNS of post symptomatic 
APP/PS1 mice compared to age matched controls. However, 
synaptosomes from the cortex of these animals exhibited a 
significant increase in ROS levels in APP/PS1 mice compared to 
controls. We further found that there was significant increase 
in the ROS levels in synaptosomes, but not PNS, of very young 
asymptomatic 1 and 3 months old APP/PS1 mice. This is a first 
demonstration of synapse specific increase in oxidative stress 
in AD mice, as young as 1 month of age, indicating that disease 
specific mechanisms operate at the synapse much before the 
appearance of any overt cellular or behavioral symptoms. The 
increase in synaptic ROS levels correlated with a small but 
significant increase in the levels of Aβ42 in the brains of 
APP/PS1 mice compared to controls. We also found a concurrent 
change in the redox status of the cytoskeletal protein, actin, 
at the synapse. As early as 1 month of age, there was a 
significant decrease in the protein level of reduced actin 
indicating that there is an increase in the level of oxidized 
actin at the synapse. This loss of reduced actin was specific to 
the fibrillar pool of actin while no significant change was 
observed in the redox status of the monomeric globular pool of 
actin. Oxidation of actin has been demonstrated to lead to its 
depolymerization. Concurrently, we found a significant loss of 
fibrillar actin in the synaptosomes of APP/PS1 mice. Actin is 
the major cytoskeletal protein at the synapse. Changes in the 
globular to fibrillar actin ratio at the synapse at early pre-
symptomatic ages in APP/PS1 mice will likely lead to structural 
and consequent functional changes at the synapse. This could 
potentially be one of the triggers of synaptic dysfunction in 
AD. 
Furthermore, changes in the Akt-mTOR signaling pathway was also 
observed in the synaptosomes of 1 month old APP/PS1 mice, which 
is sustained at 9 months. There was a significant loss of the 
mTOR-pS6K-4EBP1 axis in the synaptosomes, but not PNS, of 
APP/PS1 mice. We found that loss of Akt signaling, as evinced by 
loss of Akt phosphorylation, Akt kinase activity as well as loss 
of phosphorylation of downstream effector GSK3β, potentially 
underlies the loss of mTOR signaling. Further, the loss of Akt 
signaling is mediated by synapse specific redox modification of 
Akt and consequent interaction with the protein phosphatase 
PP2a. Loss of the Akt-mTOR signaling at the synapse is 
indicative of deficits in local protein translation. Loss of 
this essential synaptic function, which plays critical roles in 
synapse maintenance as well as synaptic plasticity during 
learning and memory, at an early age, will have long ranging 
impact on synaptic function such as long term potentiation (LTP) 
in APP/PS1 mice.  
Our study is the first demonstration of oxidative stress and 
consequent signaling changes which occur specifically at the 
synapse of very young 1 month old APP/PS1 mice. These changes 
occur much before the appearance of overt phenotype such as 
plaque deposition and behavioral dysfunction but sustain till 
the appearance of classical pathological hallmarks. Hence, the 
study demonstrates that disease progression starts much before 
previously thought and provides us a critical time window during 
which therapeutic strategies designed to delay or stop these 
changes might change the course of AD.  
 
 
